Skip to content

Investors & Media


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

Learn More

Creating value by saving sight through transformative science.

Press Releases

25-Sep-20

Graybug Appoints Three New Members to its Board of Directors

REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of

24-Sep-20

Graybug Vision Announces Pricing of Upsized Initial Public Offering

REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the pricing of its

04-Sep-20

Graybug Vision Appoints Robert Breuil as Chief Financial Officer

REDWOOD CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of Robert

View All News
Events
View All Events

SEC Filings

View All SEC Filings

Connect with Us
Sign up for ongoing news and events.
Font Resize